MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

3.75 -5.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.67

Max

3.95

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+274.23% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	8.1M 237M
Iepriekšējā atvēršanas cena	8.81
Iepriekšējā slēgšanas cena	3.75

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 17:04 UTC

Galvenie tirgus virzītāji

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026. g. 11. apr. 00:00 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Big Yachts, Big Bucks -- Barrons.com

2026. g. 10. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026. g. 10. apr. 21:01 UTC

Peļņas

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. apr. 20:31 UTC

Tirgus saruna

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026. g. 10. apr. 20:10 UTC

Iegādes, apvienošanās, pārņemšana

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026. g. 10. apr. 19:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 10. apr. 19:15 UTC

Tirgus saruna

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026. g. 10. apr. 19:08 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. apr. 19:08 UTC

Tirgus saruna

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026. g. 10. apr. 18:38 UTC

Tirgus saruna

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026. g. 10. apr. 18:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

Precious Metals Finish With Weekly Gains -- Market Talk

2026. g. 10. apr. 18:05 UTC

Tirgus saruna

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026. g. 10. apr. 17:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026. g. 10. apr. 17:26 UTC

Peļņas

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026. g. 10. apr. 17:10 UTC

Tirgus saruna

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026. g. 10. apr. 17:00 UTC

Galvenie ziņu notikumi

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026. g. 10. apr. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. apr. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 10. apr. 16:12 UTC

Peļņas

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026. g. 10. apr. 16:11 UTC

Peļņas

Partners Group: Traditional Programs Contributed $3.3B

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group 1Q New Client Demand $8.3B

2026. g. 10. apr. 16:09 UTC

Peļņas

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026. g. 10. apr. 15:54 UTC

Iegādes, apvienošanās, pārņemšana

Plenitude Completes Acquisition of Acea Energia

2026. g. 10. apr. 15:38 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

274.23% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 274.23%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.